Most Read Articles
01 Nov 2019
Discontinuation of antitumour necrosis factor (anti-TNF) therapy for perianal Crohn’s disease is highly likely to lead to relapse, with some patients even requiring defunctioning surgery, according to a study conducted across Asia.
Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).

Add-on bevacizumab improves efficacy of trifluridine/tipiracil in mCRC

Elaine Soliven
11 Jul 2019

Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.

“The combination [of FTD/TPI and bevacizumab] … is a new option in patients with chemorefractory mCRC and could be practice-changing,” said lead author Dr Per Pfeiffer from the Department of Oncology at Odense University Hospital in Odense, Denmark.

This trial involved 93 patients with chemorefractory mCRC who were randomized to receive either oral FTD/TPI (35 mg/m2 twice daily on days 1–5 and 8–12; n=47) or FTD/TPI + bevacizumab (5 mg/kg on days 1 and 15; n=46) for a treatment cycle of 28 days. [ESMO GI 2019, abstract O-014]

Patients treated with FTD/TPI + bevacizumab experienced a significantly longer PFS compared with FTD/TPI only (median, 4.6 vs 2.6 months, hazard ratio [HR], 0.45, 95 percent confidence interval [CI], 0.29–0.72; p=0.001).

Similarly, patients who received FTD/TPI + bevacizumab achieved a significantly higher OS than those who had FTD/TPI only (median, 9.4 vs 6.7 months, HR, 0.55, 95 percent CI, 0.32–0.94; p=0.03). Thirty-seven patients were still alive after a median follow-up of 11 months, as of February 2019.

Serious adverse events occurred in 21 patients in the FTD/TPI only arm and 19 patients in the FTD/TPI + bevacizumab arm.

Grade 3–4 neutropenia was more frequent in the FTD/TPI + bevacizumab group compared with the FTD/TPI only group (67.0 percent vs 38.0 percent; p<0.05). In particular, the incidence of febrile neutropenia was higher in the FTD/TPI + bevacizumab group than in the FTD/TPI only group (events, 3 vs 1).

“[Nevertheless, the FTD/TPI + bevacizumab] therapy was well tolerated with adverse events as expected,” Pfeiffer noted.

“This trial showed for the first time that [the] addition of bevacizumab to [FTD/TPI] significantly prolonged PFS and OS [in patients with chemorefractory mCRC] … compared with FTD/TPI monotherapy, with a favourable safety profile,” he concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Nov 2019
Discontinuation of antitumour necrosis factor (anti-TNF) therapy for perianal Crohn’s disease is highly likely to lead to relapse, with some patients even requiring defunctioning surgery, according to a study conducted across Asia.
Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).